Literature DB >> 31503324

Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.

Jeremy S Abramson1, Kelly E Irwin2, Matthew J Frigault1, Jorg Dietrich3, Brianne McGree1, Justin T Jordan3, Andrew J Yee1, Yi-Bin Chen1, Noopur S Raje1, Jeffrey A Barnes1, Benjamin Davis4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31503324     DOI： 10.1002/cncr.32411

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  13 in total

Review 1.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 2.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 3.  Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

Authors:  Mark B Leick; Marcela V Maus; Matthew J Frigault
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

Review 4.  HIV Lymphoma and Burkitts Lymphoma.

Authors:  Ariela Noy
Journal:  Cancer J       Date:  2020 May/Jun       Impact factor: 2.074

5.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.

Authors:  Sattva S Neelapu; Sherry Adkins; Stephen M Ansell; Joshua Brody; Mitchell S Cairo; Jonathan W Friedberg; Justin P Kline; Ronald Levy; David L Porter; Koen van Besien; Michael Werner; Michael R Bishop
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

6.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Authors:  Marcela V Maus; Sara Alexander; Michael R Bishop; Jennifer N Brudno; Colleen Callahan; Marco L Davila; Claudia Diamonte; Jorg Dietrich; Julie C Fitzgerald; Matthew J Frigault; Terry J Fry; Jennifer L Holter-Chakrabarty; Krishna V Komanduri; Daniel W Lee; Frederick L Locke; Shannon L Maude; Philip L McCarthy; Elena Mead; Sattva S Neelapu; Tomas G Neilan; Bianca D Santomasso; Elizabeth J Shpall; David T Teachey; Cameron J Turtle; Tom Whitehead; Stephan A Grupp
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 7.  Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies.

Authors:  Chaoyu Wang; Jun Liu; Yao Liu
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

8.  Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.

Authors:  Ahmed Abbasi; Stephen Peeke; Nishi Shah; Jennat Mustafa; Fariha Khatun; Amanda Lombardo; Michelly Abreu; Richard Elkind; Karen Fehn; Alyssa de Castro; Yanhua Wang; Olga Derman; Randin Nelson; Joan Uehlinger; Kira Gritsman; R Alejandro Sica; Noah Kornblum; Ioannis Mantzaris; Aditi Shastri; Murali Janakiram; Mendel Goldfinger; Amit Verma; Ira Braunschweig; Lizamarie Bachier-Rodriguez
Journal:  J Hematol Oncol       Date:  2020-01-03       Impact factor: 17.388

Review 9.  The Changing Landscape of Lymphoma Associated with HIV Infection.

Authors:  Kai Hübel
Journal:  Curr Oncol Rep       Date:  2020-08-15       Impact factor: 5.075

Review 10.  Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.

Authors:  Ibai Los-Arcos; Gloria Iacoboni; Manuela Aguilar-Guisado; Laia Alsina-Manrique; Cristina Díaz de Heredia; Claudia Fortuny-Guasch; Irene García-Cadenas; Carolina García-Vidal; Marta González-Vicent; Rafael Hernani; Mi Kwon; Marina Machado; Xavier Martínez-Gómez; Valentín Ortiz Maldonado; Carolina Pinto Pla; José Luis Piñana; Virginia Pomar; Juan Luis Reguera-Ortega; Miguel Salavert; Pere Soler-Palacín; Lourdes Vázquez-López; Pere Barba; Isabel Ruiz-Camps
Journal:  Infection       Date:  2020-09-26       Impact factor: 7.455
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.